Corporate ActionAug 6, 2026, 06:11 AM
Eupraxia Pharmaceuticals Files $300M Shelf Registration
AI Summary
Eupraxia Pharmaceuticals Inc. has filed a preliminary short form base shelf prospectus, enabling the company to offer various securities with an aggregate offering price of up to US$300,000,000. This registration covers common shares, preferred shares, debt securities, warrants, subscription receipts, and units, which can be offered from time to time over a 25-month period. The securities may be offered by the company or its securityholders and can also be used as consideration for acquisitions.
Key Highlights
- Filed preliminary short form base shelf prospectus for future offerings.
- Total aggregate offering price of securities up to US$300,000,000.
- Securities include common shares, preferred shares, debt, warrants, subscription receipts, and units.
- Offering period extends for 25 months from the prospectus's effective date.
- Common Shares listed on TSX (C$8.98 on July 31, 2026) and Nasdaq (US$6.51 on August 3, 2026).
Price Impact
More from EPRX